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Recombinant erythropoietin rapidly treats anemia in ischemic
acute renal failure
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Recombinant erythropoietin rapidly treats anemia in ischemic of most cases of ARF, it is commonly believed that ade-
acute renal failure. quate erythropoietin (EPO) response could take longer
Background. The anemia associated with acute renal failure than the course of ARF itself. Thus, anemia of ARF,
(ARF) is currently treated with blood transfusions, while the
when treatment is warranted, is usually treated with bloodanemia of chronic renal failure is treated with recombinant
transfusions. This contrasts with the anemia of chronicerythropoietin (EPO). We hypothesized that EPO treatment
during ARF could rapidly improve hemoglobin levels and be renal failure where recombinant human EPO is the cur-
a useful therapeutic approach. In addition, as tubular epithelial rent therapy of choice. In chronic renal failure, it may
cells have EPO receptors that can mediate proliferation, en- take weeks and even months to achieve the target rise
hanced recovery of renal function may occur with EPO use. in hematocrit (Hct). However, differences may exist inMethods. An established rat model of ischemic ARF was
the pathogenesis of the anemia and response to EPO instudied, using either moderate or severe ischemia. EPO was
ARF compared with chronic renal failure. We thereforeadministered in a dose of 500 or 3000 U/kg starting at time
of ischemia. Hematocrit (Hct), serum creatinine, reticulocyte hypothesized that EPO treatment during ARF could rap-
count, and mortality rate were measured. idly improve Hct levels and could be a useful therapeutic
Results. EPO treatment led to a rapid and significant in- approach. In addition, because of the presence of EPO
crease in Hct at 48 and 72 hours after moderate ischemic renal
receptors on renal tubular epithelial cells [2], we hypoth-reperfusion injury (IRI) in EPO (500 U/kg)-treated rats com-
esized that EPO may also change the course of tubularpared with control (saline treated) rats (mean 6 SE; 45.6 6
repair during ARF and thus accelerate the course of0.3% vs. 42.0 6 1.0%, P , 0.01) and (46.6 6 0.3 vs. 41.0 6 1.0,
P , 0.01, N 5 3 per group). In severe renal IRI, EPO treatment renal recovery. These hypotheses were tested in an estab-
also led to significantly increased Hct at 48 (40.0 6 4.4% vs. lished rat model of ischemic ARF [3].
36.8 6 0.3%, P , 0.01, N 5 3 per group) and 72 hours (43.5 6
1.5% vs. 34.7 6 2.3%, P , 0.01, N 5 3 per group). Higher
dose (3000 U/kg) EPO led to a more pronounced Hct increase METHODS
after severe IRI at 48 hours compared with the 500 U/kg dose
Ischemic acute renal failure(43.5 6 0.3 vs. 40.3 6 0.3, P , 0.01, N 5 3 per group). EPO
treatment during moderate or severe renal IRI did not change Ischemic ARF was induced in male Sprague-Dawley
the course of the renal dysfunction. EPO treatment (N 5 19) rats weighing 150 to 200 g as previously described in
had a significant protective effect on mortality during severe depth [3]. Briefly, rats were anesthetized with pentobar-IRI. In addition, loss of body weight during ARF was not
bital sodium injection (50 mg/kg). A midline abdominalaffected by EPO therapy.
incision under sterile conditions was followed by clamp-Conclusions. Recombinant EPO can rapidly increase Hct
and improve mortality during ARF. Human studies are war- ing of the right kidney with a vascular clip (Roboz Surgi-
ranted to evaluate the clinical applicability of this important cal Instruments, Rockville, MD, USA) with simultaneous
finding. nephrectomy of the left kidney. After each occlusion, the
clip was released at either 30 (moderate) or 45 (severe)
minutes, and reperfusion was observed. TemperatureAcute renal failure (ARF) is associated with the devel-
was maintained constant, and warm saline (5% of bodyopment of anemia [1]. Because of the short-term course
weight) was administered. After awakening, animals had
free access to food and water. All experimental tech-
Key words: hematocrit, tubular epithelial cells, reperfusion injury, in- niques were in accordance to National Institutes of Health
tensive care therapy. guidelines for animal experimentation.
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Fig. 1. A gradual decline occurs in the hematocrit (Hct) after severe
Fig. 2. Hematocrits (Hcts) of erythropoietin (EPO)-treated (500 U/kg)(45-minute clamp) renal ischemia in rats given saline injections (N 5 6).
and saline-treated groups that underwent sham surgery. Significant Hct
increasing was observed from 96 hours after surgery in EPO-treated
group. Symbols are: (s) EPO-treated (500 U/kg, N 5 5); (d) saline-
treated (N 5 5). **P , 0.01.prepared at two different dosages: 500 or 3000 U/kg. All
injections were diluted with sterile saline and adjusted
to 0.5 cc, with similar volumes of sterile saline given to
control rats. EPO was administrated intravenously at the and then reperfusion. A steady decline in Hct was ob-
time of ischemia and then subcutaneously at 24 and 48 served over the next three days (Fig. 1). Thus, this current
hours postischemia. model can be used to simulate the anemia of ARF.
Experimental groups Effect of EPO on sham surgery
The following are the experimental groups used: group Hematocrit remained stable in saline-treated, sham-
1, sham surgery, saline-treated; group 2, sham surgery, operated animals. However, in EPO-treated (500 U/kg)
EPO-treated; group 3, moderate ischemia, saline-treated; rats, a significant rise in Hct (%) was observed that
group 4, moderate ischemia, EPO-treated; group 5, se- became statistically significant 96 hours after surgery
vere ischemia, saline-treated; group 6, severe ischemia, (47.3 6 1.3 vs. 41.5 6 0.3, P , 0.01, N 5 5 per group;
EPO-treated; and group 7, severe ischemia, high-dose Fig. 2).
EPO-treated.
Effect of EPO in moderate renal ischemic renal
Outcomes measured
reperfusion injury
Blood samples were obtained from the tail vein. Serum
Moderate ischemic renal reperfusion injury (IRI; 30creatinine (SCr) was measured as a marker of renal func- minutes of ischemia) simulates reversible acute tubulartion using a Synchron LX20 Clinical system (Beckman
necrosis. This was not accompanied by development ofCulture Inc., Fullerton, CA, USA). Hct was used as an
significant anemia (Fig. 3). Administration of EPO atindicator of anemia using a Hct tube and centrifugation
500 U/kg led to a significant rise in Hct at 48 and 72at 10,000 r.p.m. for five minutes. Body weights were
hours compared with saline-treated rats with IRI (45.6 6obtained daily, and mortality was also monitored.
0.3 vs. 42.0 6 0.6, P , 0.01, N 5 3 per group, and 46.6 6
0.3 vs. 41.0 6 0.6, P , 0.01, N 5 3 per group).Statistical analysis
All values were presented as means 6 SE. Statistical Effect of EPO in severe renal IRI
analysis comparing saline-treated control and two differ-
Anemia developed rapidly in the saline-treated ratsent EPO doses was performed by analysis of variance
that underwent severe IRI (Fig. 4). In contrast, Hct wasand Fisher’s least-significant difference test. Mortality
significantly higher at 48 and 72 hours after IRI in EPOwas also compared using the Kaplan–Meier method. Sta-
(500 U/kg)-treated rats compared with saline-treated ratstistical significance was set at P , 0.05.
(41.0 6 0.6 vs. 36.5 6 0.4, P , 0.01, N 5 3 per group,
and 42.3 6 1.2 vs. 36.5 6 0.4, P , 0.01, N 5 3 per
RESULTS group). When higher doses of EPO (3000 U/kg) were
Renal ischemia reperfusion injury results in anemia administered to rats with 45 minutes of ischemia, no
further increments in Hct were observed. However, atRats (N 5 6) underwent 45 minutes of ischemia to a
single kidney, nephrectomy of the contralateral kidney, 48 hours postischemia, a more marked response in Hct
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Fig. 5. Effect of erythropoietin dose on hematocrit (Hct) during severe
Fig. 3. Hematocrits of EPO-treated (500 U/kg) and saline-treated groups renal ischemia. Hct was higher at 48 hours after IRI in the high-dose
that underwent moderate ischemic reperfusion injury (IRI; 30-minute (3000 U/kg) EPO-treated rats compared with the lower-dose (500 U/kg)
clamp). Significant increases in Hct were observed at 48 and 72 hours rats. Symbols are: (s) high-dose EPO-treated (3000 U/kg, N 5 3); (h)
after IRI in the EPO-treated group. Symbols are: (s) EPO-treated high-dose EPO-treated (500 U/kg, N 5 3); **P , 0.01.
(500 U/kg, N 5 3); (d) control (N 5 3). **P , 0.01.
Fig. 6. Serum creatinine (SCr) value (mg/dL) in the EPO-treatedFig. 4. Hematocrits of erythropoietin-treated (500 U/kg) and saline-
(500 U/kg) and saline-treated groups. Both groups underwent moderatetreated group. Both groups underwent severe IRI (45-minute clamp).
IRI (30 minutes). Baseline creatinine in both groups was ,0.3 mg/dL.Hct was significantly higher at 48 and 72 hours after IRI in EPO-treated
No different was observed at any time point. Symbols are: (s) EPO-rats compared with saline controls. Symbols are: (s) EPO-treated (500
treated (500 U/kg, N 5 3); (d) control (N 5 3).U/kg, N 5 3); (d) Control (N 5 3); **P , 0.01.
was observed compared with the 500 U/kg dose (43.5 6 Effect of EPO on body weight postischemia
0.3 vs. 40.3 6 0.3, P , 0.01, N 5 3 per group; Fig. 5). Erythropoietin can affect the hypothalamic-hormonal
axis and may have many effects independent of merely
Effect of EPO on serum creatinine postischemia correction of anemia, including reducing catabolism [5].
Growth factor administration can enhance the resolu- However, EPO treatment did not influence the loss of
tion of experimental ARF [4]. Thus, EPO, whose recep- body weight during severe renal IRI (Fig. 8). EPO treat-
tors are found on tubular epithelial cells, may modulate ment during moderate IRI was also ineffective in mitigat-
renal tubular cell recovery after ischemia [2]. However, ing the loss of body weight (data not shown).
no effect of EPO was observed on either the rise or decline
Effect of EPO on mortality after renal ischemiain SCr during moderate renal IRI (Fig. 6). Similarly, no
EPO effect was observed on the course of SCr after severe The high mortality associated with ARF continues to
IRI (Fig. 7). Even at higher doses (3000 U/kg), EPO be a serious clinical problem [6]. Mortality rates were
lacked effect on the course of SCr during severe IRI (data compared in EPO and untreated animals. All rats sur-
vived after moderate IRI. However, after severe IRI,not shown).
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Fig. 7. Serum creatinine (SCr) values in (mg/dL) EPO-treated (500 U/kg)
and saline-treated groups after severe renal ischemia (45-min clamp).
No difference was observed at any time point. No effect on SCr was
Fig. 9. Effect of EPO on mortality after IRI. Mortality was pronouncedseen even when higher dose EPO (3000 U/kg) was used (data not
after severe (45 minutes) renal IRI. EPO (3000 U/kg) treatment signifi-shown). Symbols are: (s) EPO-treated (500 U/kg, N 5 3); (d) control
cantly improved mortality (P , 0.05) after severe IRI. All rats survived(N 5 3).
after moderate IRI at 72 hours (data not shown). Symbols are: (s)
EPO-treated (N 5 19); (d) Control (N 5 17).
DISCUSSION
Anemia is often observed during ARF [7]. We hypoth-
esized that recombinant EPO would be a useful therapy
in ischemic ARF. We found that EPO can rapidly raise
Hct during moderate and severe ischemic ARF in rats.
The likely mechanism is by increasing erythrocyte pro-
duction, as evidenced by an increased reticulocyte count
after EPO treatment. Importantly, EPO treatment re-
sulted in a significant improvement in mortality after
severe ischemic injury. However, EPO administration
did not significantly influence the course of the SCr or
body weight.
It is useful to compare the Hct responses in our studiesFig. 8. Change in body weight after severe renal ischemia. More severe
weight loss is seen in the severe renal IRI compared with moderate to another model of ARF, cisplatin-induced ARF. In this
IRI. However, no significant difference was seen in the saline-treated model, EPO was administrated during cisplatin-inducedgroup compared with the EPO-treated group (500 U/kg). The higher-
ARF in rats [8]. There were no significantly differencesdose EPO (3000 U/kg) group did not differ from saline group either
(data not shown). Symbols are: (s) EPO-treated (3000 U/kg, N 5 3); in Hct between the two groups of rats on day 4. However,
(d) control (N 5 3). the EPO-treated group showed a significantly higher Hct
level compared with untreated ARF group on day 9
after cisplatin. This cisplatin study also showed that renal
function and body weight was improved in the EPO-substantial mortality ensues (Fig. 9). EPO treatment sig-
treated group nine days after cisplatin [8]. In our currentnificantly improves survival when rats were followed 96
study using an IRI model of ARF, we found a much
hours postischemia. more rapid response after EPO, and no effect on body
weight. However, cisplatin toxicity is likely to have addi-Effect of EPO on reticulocyte count after
tional effects, particularly on the bone marrow, than
renal ischemia what is observed after IRI.
Reticulocyte counts, reflective of erythrocyte produc- The rapid response in Hct to EPO in experimental
tion, were decreased 48 hours after 45 minutes of renal ARF that we observed was quite different from that
ischemia (7.5 6 0.7 vs. 5.6 6 0.4, P , 0.05). However, seen in chronic renal failure. During chronic renal fail-
EPO treatment significantly increased the reticulocyte ure, EPO production is depressed with inappropriately
low plasma levels throughout the uremic phase [9]. Manycount during ARF (6.9 6 0.3, P , 0.05).
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other factors contribute to anemia, including reduced a protracted ARF model could have led to improvement
red cell life span, iron deficiency, chronic inflammation, in SCr. In a study of cis-platinum–induced ARF in which
and contaminants of hemodialysis. The pathophysiology EPO was administered for nine consecutive days, renal
of anemia in ARF is likely to be complex. A significant functional changes were apparent after nine days but
reduction in serum haptoglobin and an increase in serum not at four days [19].
lactate dehydrogenase in ARF suggest that that hemoly- Given the high rate of mortality and catabolism associ-
sis is a contributory factor in the initial fall in Hct in ated with native kidney ARF [20], we were interested
ARF [8]. Production of EPO has also been demonstrated in the possible effect of EPO on mortality and body
to be reduced in rats and humans during ARF [10, 11]. weight. It has been shown that that the administration
The pathogenesis is not well understood. Other factors of EPO provided a beneficial effect on the body weight,
underlying the anemia include bleeding, hemolysis, blood Hct, and healing rate in rats seven days following a large
sequestration, and resistance to EPO [7]. It is also possi- bowel operation [21]. In our current study, both in mod-
ble that saline treatment during our surgical protocol erate and severe IRI, the decrease in body weights during
may have contributed to a dilutional component to the ARF was not affected by EPO. However, a marked
anemia, but in this regard, all rats received similar quanti- improvement in mortality was observed in EPO-treated
ties of saline. Despite the partial knowledge underlying rats after severe IRI. It is unclear as to the mechanisms of
the anemia of ARF, EPO therapy could still be a useful the decreased mortality. One possibility is that although
therapy in ARF as it is for CRF. there were no significant differences in SCr, more sensitive
We found that EPO at 500 U/kg for three consecutive tests such as inulin clearances would have detected small
doses increased Hct rapidly in rats with normal renal increases in glomerular filtration rate (GFR) after EPO
function. Previous studies have also looked at EPO’s treatment. These small increases in GFR may have been
effect in normal rats. EPO administered twice weekly adequate to improve mortality. Another possibility is
(150 U/kg) had no significant effects on Hct after one that EPO may have reduced the lung dysfunction and
week compared with controls [12]. In another study in systemic inflammatory state that has been associated
which EPO was administrated to normal rats, a signifi- with renal IRI [22].
cant increase in Hct was observed at day 3 [13]. Our current data demonstrate that EPO treatment
When the Hct response to EPO is rapid, changes can during ARF rapidly improves Hct levels and could be a
be detected early in reticulocytes. In a study in which EPO useful therapeutic approach, especially in the intensive
was administrated 250 U/kg and 1250 U/kg, an increase care unit. In humans, at least one case report exists de-
in reticulocytes began at 24 hours and reached the peak
scribing EPO therapy for anemia with ARF [23]. A prop-
at 72 to 96 hours after injection of EPO [14]. In the current
erly designed clinical trial with an adequate number ofstudy, we did not specifically investigate the mechanisms
patients will be required prior to justifying the routinefor the anemia of ARF. However, the increase in reticu-
use of EPO in patients with ARF.locyte count in the EPO-treated groups makes it likely
that the effect we observed was based on increased red
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